NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Written by / Agency / Source: General Electric Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes - GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC - DARPA.mil / GEGlobalResearch.com.com
GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes

 

NewswireToday - /newswire/ - Niskayuna, NY, United States, 2018/09/05 - GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC - DARPA.mil / GEGlobalResearch.com.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• GE researchers to demonstrate concepts around neuromodulation technology to treat Diabetes during DARPA’s D60 Conference;
• Emerging scientific evidence shows that nervous system dysfunction may be a key contributor to many chronic diseases;
• Promising research in bioelectronic medicine suggests that stimulating and monitoring the human nervous system could create new treatments that replace drugs.

Could non-invasive devices replace drugs and regular insulin injections in the future treatment of diabetes? This is a central question a team of GE scientists are exploring as part of a research project with DARPA (darpa.mil) worth up to $2.9 million. GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC.

As part of the 3-year program, the GE Bioelectronic medicine team aims to demonstrate that a novel, non-invasive, stimulation technique can be used to reverse or treat diabetes in pre-clinical models, instead of the typical drugs associated with treatments today. The team hopes that the results indicate the ability to prevent the onset of metabolic dysfunction (associated with the onset of diabetes), and that the GE team can progress toward safely testing and applying this technology in the clinic.

“Today’s drug treatments and monitoring methods for diabetes can be uncomfortable and time consuming, and create side-effects for patients,” said Victoria Cotero, a PhD and Biologist at GE Global Research who contributes to the DARPA project. “Our project with DARPA aims to find a better alternative that treats diabetes with non-invasive medical devices without the side effects associated with drug treatments.”

This project is part of a growing body of research in the field of bioelectronic medicine that is exploring new ways to treat chronic diseases such as diabetes by using electronic devices to correct dysfunctions in the nervous system that are believed to be key contributing factors to these diseases. GE scientists have developed a novel, potentially breakthrough approach that could restore nerve signals to a healthy state using non-invasive devices that stimulate metabolic biosystems and produce drug-like effects, but with greater precision than traditional treatments, and with fewer side effects.

The GE Bioelectronic medicine team is located at GE’s Global Research Center in Upstate New York. This interdisciplinary team of scientists and engineers works at the intersection of biology, physics and engineering and has deep connections to other top academic and clinical collaborators in the field.

Recently, members of the GE team were part of groundbreaking work led by the Feinstein Institute for Medical Research to read and interpret nerve signals in the body. The projects with DARPA and Feinstein are part of a growing number of research initiatives that the Bioelectronic medicine team is exploring to transform the diagnosis, treatment and monitoring of diseases.

“Given GE’s decades of innovation in medical imaging modalities, our growing body of research and published work in biomedical research and our considerable network of academic and clinical collaborators, GE Global Research is in a unique position to help drive the emerging field of non-invasive neuromodulation and enable revolutionary new treatments for diabetes and other chronic diseases,” Chris Puleo, a GE biomedical engineer and principal investigator of the DARPA project said.

About GE Global Research

GE Global Research (geglobalresearch.com) is GE’s innovation powerhouse where research meets reality. We are a world-class team of 1,000+ scientific, engineering and marketing minds (600+ Ph. Ds), working at the intersection of physics and markets, physical and digital technologies, and across a broad set of industries to deliver world-changing innovations and capabilities for our customers.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Todd Alhart - GE.com 
518-387-7914 todd.alhart[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health / Surgery Most Recent Related Newswires:

Syapse Awarded 2021 Technology Innovation Leadership Award by Frost & Sullivan for Accelerating Real-world Care Delivery
Lumeon Commended by Frost & Sullivan for Enabling Digital Transformation in Healthcare
Payment Integrity Solutions Enable Healthcare Plans to Optimize Processes and Maximize Returns Finds Frost & Sullivan
Menopause to Become the Next Game-changer in the Global Femtech Solutions Industry by 2025 Finds Frost & Sullivan
Innovative MedTech Business Models Will Enable Cost-effective, Decentralized and Patient-centric Care Finds Frost & Sullivan
Data Monetization a Must for MedTech Industry to Evolve Toward Real-World Evidence and Precision Medicine Finds Frost & Sullivan
InterSystems Partners with Cognetivity on Ground-breaking AI Solution for Early Dementia Detection
Humimic Medical, Partners Team Up to Make A Difference in South Carolina COVID Battle
Adoption of HaH Model Surged Eight-fold with the Availability of Advanced Remote Monitoring and Digital Health Solutions Finds Frost & Sullivan
Major Innovation Announcement Planned, SC Life Sciences Conference Shatters Registration Record
South Carolina Life Sciences Conference Adds Top Executives from Microsoft, Alphabet, PhRMA
SC Life Sciences Conference to Feature BIO Global Executive February 16-17
20Lighter Announces Orthopedic Surgery Alliance
Calmerry Introduces Individual, Couples and Family Online Therapy with Licensed Professionals
CoverMyMeds Lauded by Frost & Sullivan for Seamlessly Connecting the Healthcare Network with its Industry-leading ePA Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)